How the Approval of Aducanumab Will Change Alzheimer’s Trials

Xtalks Life Science Podcast

English - August 25, 2021 09:00 - 27 minutes - 19.3 MB
Life Sciences Science pharma pharmaceuticals biotech biotechnology medical device life science drug safety clinical research clinical trials drug development Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised Individuals

Next Episode: Why Antimicrobial Resistance is a Silent Pandemic

In this episode, Sarah presents three ways that Alzheimer’s trials will change now that Biogen’s Aduhelm (aducanumab) has been approved by the FDA. The team discusses whether placebo-controlled trials are still ethical and how ongoing dementia studies can manage patient attrition. Can trials pivot to allow patients to aducanumab as a background therapy?

The hosts also discuss how the price of aducanumab may limit patient access, and what it might take for payers to cover the cost of this pricey drug.

Read the full article here:

AAIC 2021: Six Ways the Approval of Aducanumab Will Change Alzheimer’s Clinical Trials

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Twitter Mentions

@xtalks